Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II clinical trial of ISX9-CPC

X
Trial Profile

A Phase I/II clinical trial of ISX9-CPC

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISX9 CPC (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2025 New trial record
    • 13 Jan 2025 According to a IPS HEART media release, company is also pursuing ongoing partnerships with various large pharmaceutical companies while attending the J.P. Morgan Healthcare Conference to partner with them to help rapidly advance both therapies to the clinic.
    • 13 Jan 2025 According to a IPS HEART media release, given the successful completion of second pre-IND meeting with the FDA last year (attended by 4 FDA branch chiefs), which also included approving proposed/submitted Phase I/II clinical trial design, for advancing both therapeutics (both cardiac muscle and skeletal muscle in muscular dystrophy) to the clinic.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top